Ken Westover is a practicing thoracic radiation oncologist with expertise in structural biology, biochemistry, cancer biology and structure-based drug development. His team, together with collaborators, developed inhibitors to other kinase cancer targets including mTOR, TAK1 and HER3. Additionally, the Westover lab, together with collaborators, developed covalent GTP-competitive inhibitors and quinazoline scaffold switch 2 pocket inhibitors of KRAS G12C, the most common RAS mutation found in lung cancer. Recent work has established a model for RAS dimerization and validated the importance of RAS dimerization for biological function. Finally, multiple efforts are directed at understanding differences in RAS cancer allele-specific mechanisms of activation. Clinically Dr. Westover studies radiation treatments utilizing hypofractionated radiation such as stereotactic body radiation therapy (SBRT).